DeepUll
Developer of automated direct-from-blood molecular diagnostic technology for rapid identification of bloodstream pathogens and antibiotic-resistance markers. The company is developing an automated sample-to-result platform that extracts total microbial DNA from whole blood and aims to deliver a broad panel of pathogen and resistance results in about 1 hour. Products are under development and not currently available for diagnostic use.
Industries
Nr. of Employees
small (1-50)
Products
Automated direct-from-blood molecular diagnostic system (prototype)
Automated instrument that extracts total microbial DNA from whole blood and runs a molecular assay to identify pathogens and resistance markers with an intended ~1-hour turnaround. Designed for continuous loading (up to 8 samples), STAT prioritization, and LIS connectivity.
Direct-from-blood bloodstream infection (BSI) molecular test (prototype)
Assay designed for use with whole blood (8 mL) to detect a broad panel of sepsis-causing pathogens and antibiotic resistance markers; preliminary data show higher pathogen detection compared to blood culture and high concordance with positive cultures.
Automated direct-from-blood molecular diagnostic system (prototype)
Automated instrument that extracts total microbial DNA from whole blood and runs a molecular assay to identify pathogens and resistance markers with an intended ~1-hour turnaround. Designed for continuous loading (up to 8 samples), STAT prioritization, and LIS connectivity.
Direct-from-blood bloodstream infection (BSI) molecular test (prototype)
Assay designed for use with whole blood (8 mL) to detect a broad panel of sepsis-causing pathogens and antibiotic resistance markers; preliminary data show higher pathogen detection compared to blood culture and high concordance with positive cultures.
Expertise Areas
- Direct-from-blood molecular diagnostics
- Sepsis and bloodstream infection testing
- Automated sample-to-answer diagnostic platforms
- Microbial cell-free DNA analysis
Key Technologies
- Multiplex PCR
- Total microbial DNA extraction from whole blood
- Microbial cell-free DNA detection
- Automated sample-to-result instrumentation
News & Updates
Prospectively obtained specimens from septic patients showed high concordance with positive blood culture and detection of more than twice as many clinically relevant pathogens compared to blood culture.
Development project funded by MCIN/AEI and the European Union NextGenerationEU / PRTR under project code CPP2021-008464.
Prospectively obtained specimens from septic patients showed high concordance with positive blood culture and detection of more than twice as many clinically relevant pathogens compared to blood culture.
Development project funded by MCIN/AEI and the European Union NextGenerationEU / PRTR under project code CPP2021-008464.